Rosemary S. Harrison is Head of Rare Diseases at Imbria Pharmaceuticals. Rosemary has 15 years of experience in translating early science into scientific strategy, operationalizing strategy and building organizations. She joined Imbria from RA Capital Management where she was Head of Research (TechAtlas). Prior to RA, she was Head of Strategy and Portfolio Management at Novartis Institutes for Biomedical Research. Before joining Novartis, Rosemary had roles of increasing responsibility in healthcare consulting at Bain & Company with a focus on biotech and pharmaceuticals. She holds a Ph.D. and B. Biotech (Hons, Medal) from The University of Queensland.